LB Pharmaceuticals discussed its lb-102 candidate and its goal of safer psychiatric treatment at the TD Cowen summit.
LB Pharmaceuticals appeared at the TD Cowen summit, where the company addressed its pipeline candidate lb-102 and its aim to pursue safer psychiatric therapy.
Further details on lb-102's clinical profile or development timeline were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
